Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06898450 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
A Phase 1 study of Advanced Solid Tumors Cancer and MSI-H Cancer, sponsored by Nimbus Wadjet.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 20
- Study locations
NCT06898450 is a Phase 1 study of Advanced Solid Tumors Cancer and MSI-H Cancer that is actively recruiting participants, run by Nimbus Wadjet. The registered enrollment target is 134 participants, below the 339-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06898450, a Phase 1 study of Advanced Solid Tumors Cancer and MSI-H Cancer, is actively recruiting participants, sponsored by Nimbus Wadjet.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.
Conditions Studied
Interventions
- DRUG NDI-219216
Study Locations (20)
Other
- Hôpital Saint-Antoine - Assistance Publique-Hopitaux de Paris (AP-HP) - Paris
- Centre Hospitalier Universitaire (CHU) de Poitiers - Poitiers
- START Dublin - Dublin
- START Lisbon - Lisbon
North Carolina
- Levine Cancer Center - Charlotte
- Atrium Health Wake Forest Baptist Center - Winston-Salem
Virginia
- University of Virginia Emily Couric Clinical Cancer Center - Charlottesville
- Virginia Cancer Specialists, P.C. - Fairfax - Fairfax
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Illinois
- University of Chicago Medicine - Chicago
Kentucky
- University of Louisville James Graham Brown Cancer Center - Louisville
New York
- Cayuga Cancer Center - Ithaca
Ohio
- Taylor Cancer Research Center - Maumee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06898450
The ClinicalTrials.gov registry entry for NCT06898450 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 339-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (60% lower). The listed sponsor is Nimbus Wadjet, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 1 intervention - of which NDI-219216 is the first listed.
NCT06898450 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT06898450 about?
NCT06898450 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.". The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? Wh...
What is the current status of trial NCT06898450?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2025-03-31. Estimated completion is 2031-12.
What conditions does trial NCT06898450 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer, MSI-H Cancer.
What interventions are being tested in trial NCT06898450?
The interventions under investigation include: NDI-219216 (DRUG).
Who is sponsoring clinical trial NCT06898450?
This trial is sponsored by Nimbus Wadjet, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06898450 being conducted?
This trial has 20 study locations across California, Illinois, Kentucky, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
ORB-021 In Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.